To investigate the effect of zoledronic acid (ZA) on fracture rate in children and young adults with both primary and secondary skeletal fragility.
Key Findings:
Overall median fracture rate decreased from 0.6 (IQR 0.3-1.1) to 0 (IQR 0-0.4) fractures per year (P < .001).
Significant reductions in fracture rates were observed in both primary (1.0 [IQR 0.6-1.5] to 0.3 [IQR 0-0.6]) and secondary (0.5 [IQR 0.1-0.8] to 0 [IQR 0-0.3]) skeletal fragility.
Fracture rate reductions persisted when limited to long bone or long bone plus spine fractures.
Interpretation:
ZA treatment is associated with significant declines in fracture rates among children and young adults with skeletal fragility, indicating its potential as an effective intervention.
Limitations:
Retrospective design limits causality inference.
Sample size may not represent all pediatric populations with skeletal fragility.
Lack of long-term follow-up data on fracture rates post-treatment.
Conclusion:
ZA is effective in reducing fracture rates in pediatric patients with skeletal fragility, supporting its use in clinical practice for fracture prevention.
National survey findings suggest many US adults report making health decisions based on social media despite widespread concerns about the accuracy of health information shared to the platforms.
